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ABSTRACT
Background There is currently great interest in the
incorporation of genetic susceptibility loci into screening
models to identify individuals at high risk of disease.
Here, we present the ﬁrst risk prediction model including
all 46 known genetic loci associated with rheumatoid
arthritis (RA).
Methods Aweighted genetic risk score (wGRS) was
created using 45 RA non-human leucocyte antigen (HLA)
susceptibility loci, imputed amino acids at HLA-DRB1 (11,
71 and 74), HLA-DPB1 (position 9) HLA-B (position 9)
and gender. The wGRS was tested in 11 366 RA cases
and 15 489 healthy controls. The risk of developing RA
was estimated using logistic regression by dividing the
wGRS into quintiles. The ability of the wGRS to
discriminate between cases and controls was assessed by
receiver operator characteristic analysis and discrimination
improvement tests.
Results Individuals in the highest risk group showed
signiﬁcantly increased odds of developing anti-cyclic
citrullinated peptide-positive RA compared to the lowest
risk group (OR 27.13, 95% CI 23.70 to 31.05). The
wGRS was validated in an independent cohort that
showed similar results (area under the curve 0.78, OR
18.00, 95% CI 13.67 to 23.71). Comparison of the full
wGRS with a wGRS in which HLA amino acids were
replaced by a HLA tag single-nucleotide polymorphism
showed a signiﬁcant loss of sensitivity and speciﬁcity.
Conclusions Our study suggests that in RA, even when
using all known genetic susceptibility variants, prediction
performance remains modest; while this is insufﬁciently
accurate for general population screening, it may prove of
more use in targeted studies. Our study has also
highlighted the importance of including HLAvariation in
risk prediction models.
INTRODUCTION
The recent advances in complex disease genetics
has prompted discussion as to how this information
could be used in personalised medicine and risk
prediction. Predicting the development of disease,
or progression to severe disease is one of the ultim-
ate aims of genetic and epidemiological research.
Accurate risk prediction would allow targeted pre-
ventive treatments, such as lifestyle or even
pharmacological intervention.
Rheumatoid arthritis (RA) is a typical complex
genetic disease, with the strongest genetic associ-
ation lying within the major histocompatibility
complex (MHC). In 2012 a study in this region
identiﬁed ﬁve amino acids in three human leucocyte
antigen (HLA) proteins (HLA-DRB1, HLA-DPB1
and HLA-B) explaining most of the association
between the MHC and RA.
1 In addition, the most
recent study to identify RA-associated loci compre-
hensively (Immunochip), has identiﬁed novel loci
associated with disease, bringing the total number of
Caucasian RA susceptibility loci to 48 (45 non HLA
loci plus three HLA loci).
2
Therefore, it is now timely to examine the predict-
ive ability of these genetic data. The aims of this
study were, ﬁrst, to extend previous analysis
3–6 by
creating a weighted genetic risk score (wGRS) includ-
ing all known Caucasian RA susceptibility loci and
epidemiological risk factors when possible (smoking,
gender); second, to compare models to identify the
most informative and economical method for inclu-
sion into a screening model; third, to assess the per-
formance of the wGRS in speciﬁc patient subgroups
stratiﬁed by the presence of autoantibodies.
METHODS
Samples
Cases and controls were selected from the UK,
USA, Sweden, The Netherlands and Spain as
described previously.
2 All cases were Caucasian,
over the age of 18 years and satisﬁed 1987
American College of Rheumatology criteria for RA
modiﬁed for genetic studies.
7 For further informa-
tion regarding the sample collections used in this
study see the supplementary note (available online
only).
Genotyping
Genotyping was carried out using a custom
designed Illumina Inﬁnium array, ‘immunochip’,
and Illumina iScan technology, and quality control
of the data was carried out as described previously.
2
Statistical analysis
A wGRS was generated using a combination of RA
susceptibility loci. Analysis was carried out using
STATA V .11.0 (http://www.stata.com). wGRS were
created using the 45 non-HLA loci conﬁrmed to be
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2 and then including either a
HLA-DRB1 tag single-nucleotide polymorphism (SNP)
(rs660895) or imputed HLA-DRB1 amino acids 11, 71, 74 and
imputed amino acids nine at HLA-DPB1 and HLA-B,
1 in order
to identify the most informative and economical method to
incorporate HLA into a risk screening model. SNP-only and
HLA-only models were also generated to determine the contri-
bution of the disease-associated SNPs, which have modest effect
sizes, to the risk score.
We assessed the accuracy of the imputation by comparing the
imputed HLA-DRB1 alleles to the genotyped HLA-DRB1 alleles
in a subset of 1894 samples.
Each wGRS was generated by weighting each allele using the
natural log of the published OR reported in Eyre et al
2 or, in
the case of the imputed HLA amino acids, were weighted by
published OR for each haplotype as shown in Raychaudhuri
et al.
1 The SNP rs10739580, rs39984 and rs78560100 were
not available in the discovery data, therefore the following
proxies were selected rs10739579, rs434816 and rs62323881,
respectively. Individuals with missing SNP genotypes were
assigned a value that was equal to two times the minor allele fre-
quency.
6 Logistic regression was used to calculate OR and p
values for each wGRS.
Environmental factors also contribute to the risk of RA, there-
fore gender and smoking were also incorporated into the model
when data were available. Gender was available for all indivi-
duals and was weighted by the natural log of the OR in our
cohort (OR 2.00) as the association varies by age.
Smoking data were available for controls from the 1958 birth
cohort and a subset of RA patients from the UK, speciﬁcally
recruited as part of the Norfolk Arthritis Register (NOAR).
Smoking status was coded as 0 for never smokers and 1 for ever
smokers.
To determine how well the wGRS discriminates between
cases and controls we generated receiver operator characteristic
(ROC) curves, deﬁning the sensitivity and speciﬁcity of each
wGRS, and calculated the area under the curve (AUC). It has
previously been shown that susceptibility factors would need an
exceptionally large OR to have a signiﬁcant impact on the AUC,
and that it may be more appropriate to assess reclassiﬁcation
rather than discrimination of a model.
89Therefore, integrated
discrimination improvement (IDI) tests were carried out using
STATA to determine the change in probability between the
models. IDI is a measure of overall improvement in sensitivity
and speciﬁcity, which allows the comparison of models and
assessment of how much improvement is made by the addition
of other variables.
10 In our case–control study the probability of
RA is increased compared to the general population due to a
large number of cases; however, we have used IDI tests to
compare models within our dataset and not to generalise to the
population as a whole.
Continuous net reclassiﬁcation improvement tests
11 were used
to quantify the overall improvement of reclassiﬁcation between
models, that is, the amount of correct reclassiﬁcation among
cases and controls.
Finally the wGRS scores were split into quintiles. Individuals
in the 5th quintile were classed as high risk, allowing us to cal-
culate sensitivity and speciﬁcity for each model.
Validation of wGRS
As several of the RA susceptibility loci included in the wGRS
were identiﬁed in the cohort used in this study, the wGRS were
tested in an independent European cohort of 2206 RA cases
and 1863 healthy controls for validation. The SNP rs10683701
and rs13397 were not available in the validation dataset, there-
fore rs7979246 was used as a proxy (r
2=0.98) for
rs10683701, no proxy was available for rs13397.
The samples were from the Consortium of Rheumatology
Researchers of North America (CORRONA) registry and the
Informatics for Integrating Biology and the Bedside (I2B2)
centre. For the CORRONA samples, RA patients from the regis-
try were recruited and consented for a genetics substudy from
40 rheumatology ofﬁce sites.
Samples were genotyped using the custom designed Illumina
Inﬁnium genotyping chip ‘immunochip’. Genotype clustering
was carried out using Illumina’s Beadstudio custom cluster ﬁles.
SNP and sample quality control thresholds were applied in
PLINK (SNP missingness >0.02, sample call rate <0.9). To
identify related individuals’ identity by descent analysis was
carried out using a set of high quality (missingness <0.002,
minor allele frequency >0.1) and linkage disequilibrium pruned
(r
2<0.2) SNPs. Samples with a PI-HAT greater than 0.2 were
removed. Principal components analysis was carried in
EIGENSOFT, using HapMap3 samples as reference.
RESULTS
Data quality control
Sample and genotype quality control was carried out as
described previously.
2 HLA imputation accuracy was shown to
be 97% at two digit resolution and 91% at four digit resolution.
Quality control of the imputed HLA data excluded 439 samples
due to missing data or multiple haplotypes being assigned,
leaving 11 366 cases and 15 489 controls for analysis (described
previously).
2 Cohort characteristics can be seen in table 1.
Table 1 Cohort characteristic for the discovery cohort (11 366 cases and 15 489 controls)
Collection
Cases Controls
All Women (%) ACPA+ ACPA− All Women (%)
UK 3768 2772 (73.57) 2360 954 8051 3504 (43.52)
Swedish EIRA 2759 1943 (70.42) 960 562 1939 1415 (72.98)
USA 2534 1908 (75.30) 1801 2726 2133 1383 (64.84)
Dutch 647 428 (66.15) 329 301 2004 844 (42.12)
Swedish UMEA 852 594 (69.72) 524 242 963 659 (68.43)
Spanish 806 599 (74.32) 396 216 399 260 (65.16)
Total 11 366 8244 (72.53) 6370 2868 15 489 8065 (52.07)
Rheumatoid arthritis (RA) cases and controls were assembled from a number of different studies from six centres across five countries. RA cases were classified as anti-citrullinated
protein antibody (ACPA) positive (ACPA+) or ACPA negative (ACPA−). Swedish EIRA, Swedish Epidemiological Investigation of Rheumatoid Arthritis; Swedish Umea, Swedish.
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Smoking data were available for 1978 anti-cyclic citrullinated
peptide (CCP) positive cases and 1224 controls. We tested the
association of smoking with RA in our dataset and found that
smoking was not associated with an increased risk of RA (OR
0.78, 95% CI 0.67 to 0.91, p=0.002) in our data.
Analysis of wGRS
Logistic regression showed that all calculated wGRS scores were
good predictors of RA (table 2). The ability of the model to dis-
criminate correctly between individuals with RA and those
without RA was measured by the AUC and was shown to be
0.74 (wGRSfull_G) (table 2) this was improved in
anti-CCP-positive individuals to AUC 0.79 (table 2).
The AUC was improved by replacing the HLA-DRB1 tag SNP
with imputed HLA variation at HLA-DRB1, HLA-DPB1 and
HLA-B (wGRStag_G AUC 0.70, wGRSfull_G AUC 0.79) (in
CCP-positive individuals) (table 2, ﬁgure 1). IDI tests showed an
increase in sensitivity and speciﬁcity of 11%, and continuous
net reclassiﬁcation tests showed that including all variation in
the HLA over a HLA tag SNP improves the probability of cor-
rectly identifying a high-risk individual to 70.09% from
64.21%, and showed an overall reclassiﬁcation improvement of
66.65% between models.
Comparing the wGRSfull_G (in CCP-positive individuals) to
a model containing only imputed variation in the HLA and
gender (wGRSHLA_G) showed that the addition of the suscep-
tibility SNPs to the model only slightly improved the ROC AUC
(0.76 to 0.79, respectively) (table 2, ﬁgure 1).
As the wGRS performed best in anti-CCP-positive individuals,
the remainder of the analysis was restricted to this subgroup.
The comparison of full model wGRSfull_G and
wGRSHLA_G including HLA variation and gender using likeli-
hood ratio tests showed a signiﬁcant difference between the two
(LR χ
2 1130.72, χdist p=1.91×10
−207). The overall discrimin-
ation improvement was 5% and continuous net reclassiﬁcation
improvement tests, which consider the reclassiﬁcation of cases
and controls separately showed a 44% improvement in reclassiﬁ-
cation between models (p=4.16×10
−189).
The wGRSfull_G was split into ﬁve quintiles; individuals in
the 5th quintile were classed as high risk (ﬁgure 2). Classifying
everyone with a wGRS greater than 9.75 as high risk, 9.7% of
our control population were classiﬁed into this high-risk group.
Logistic regression was used to compare individuals in the high-
risk group to individuals in the lowest risk group (quintile 1) and
individuals in the median-risk group (quintile 3). The results
showed that the odds of developing RA were signiﬁcantly
increased in individuals in the highest risk group compared to indi-
viduals in the lowest risk group (OR 27.13, 95% CI 23.70 to
31.05) and individuals in the median-risk group (OR 6.38, 95%
CI 5.81 to 7.02) (table 3).
The sensitivity and speciﬁcity of the wGRSfull_G was calcu-
lated (table 2), showing that, although the model has a high
AUC, it still lacks in sensitivity (44%), resulting in a high pro-
portion of individuals with RA being misclassiﬁed as non-RA.
Addition of smoking to the model
The addition of smoking to the wGRS slightly improved the
AUC to 0.80 in anti-CCP-positive individuals (1978 cases (1269
smokers) and 1224 controls (851 smokers)). IDI tests showed
no improvement in sensitivity and speciﬁcity, and total continu-
ous net reclassiﬁcation (by adding smoking) showed a small
increase of 10.74% (p=0.0016). This minimal improvement is
not surprising given the lack of association between smoking
and RA in our data.
Validation
SNP genotypes for the 45 RA associated loci and a HLA tag
SNP were available for 2206 RA cases and 1863 healthy con-
trols, independent from the test cohort.
Eleven samples were excluded after HLA imputation due to
multiple ambiguous alleles being assigned, two samples were
excluded due to missing wGRS; 2200 cases and 1856 controls
remained for analysis.
All wGRS were tested in an independent cohort of samples
(2200 RA cases and 1856 controls). The full model including
gender (wGRSfull_G) showed good discrimination between
individuals with RA and healthy individuals (ROC AUC 0.72);
however, this was less than was seen in the discovery dataset
(AUC 0.73).
This was further increased in CCP-positive individuals (1406
cases, 1856 controls) (AUC 0.78). These results were similar to
those seen in the discovery dataset of 11 366 RA cases and
15 489 healthy controls.
Again, comparison of the full wGRS containing all 45 SNPs,
HLA variation and gender to the HLA-only model showed little
difference between the models (AUC 0.78, AUC 0.76, respect-
ively) (ﬁgure 3, table 2), showing that, as expected, the contri-
bution of each individual susceptibility variant is minimal.
As before, the wGRS was split into quintiles and comparison
of the high-risk group to the low-risk and median-risk groups
showed a signiﬁcantly increased risk of RA (in CCP-positive
cases and healthy controls: OR 18.00, 95% CI 13.67 to 23.71,
OR 4.92, 95% CI 3.87 to 6.26, respectively) (table 3).
DISCUSSION
We present the ﬁrst weighted genetic risk prediction score for
RA using recently published genetic loci and in the largest
cohort to date. We have shown a signiﬁcant association between
all models tested, with the odds of RA being increased to 27.13
(95% CI 23.70 to 31.05) in CCP-positive individuals when
compared to the lowest risk group (OR 6.38 when compared to
the median-risk group, 95% CI 5.81 to 7.02). However, 9.70%
of healthy controls were classed as high risk, showing that a sub-
stantial proportion of the general population would be classiﬁed
as being at high risk of developing RA, whereas only 1% will
develop the disease. The wGRSfull_G shows increased discrim-
ination when in anti-CCP-positive cases compared to controls
(AUC 0.79), and improvement on models previously tested
using 31 loci and HLA-DRB1 in seropositive RA (AUC 0.65).
6
However, it must be noted that the majority of loci in the
wGRS have been associated with CCP-positive disease only, par-
ticularly HLA-DRB1 alleles that predispose to autoantibody-
positive erosive disease.
Replacing the single HLA-DRB1 tag SNP with the ﬁve HLA
amino acids (wGRSfull_G) not only showed a signiﬁcant
improvement in AUC (from 0.70 to 0.79), but also showed that
the inclusion of imputed amino acids at HLA-DRB1,
HLA-DPB1 and HLA-B provided signiﬁcantly more information
and increased the reclassiﬁcation of individuals by 66.65%, sug-
gesting that the inclusion of HLA variation in risk prediction
models will be essential.
The ultimate aim of genetic screening models is that they can
be used in the general population to identify at-risk individuals
for monitoring or intervention. In order to be of use, a risk pre-
diction model needs to be sensitive, speciﬁc and cost efﬁcient,
and will therefore include as few markers as possible to lower
Clinical and epidemiological research
172 Yarwood A, et al. Ann Rheum Dis 2015;74:170–176. doi:10.1136/annrheumdis-2013-204133Table 2 The association of each wGRS model with RA
wGRS 45 Susceptibility SNPs HLA-DRB1 tag SNP 5 Amino acids Smoking Gender OR 95% CI AUC Threshold Sensitivity (%) Specificity (%)
Sample size
Cases Controls
Discovery dataset
wGRSfull_G + − + − + 2.01 1.96 2.05 0.7375 >9.85 35 91 11 366 15 489
Anti-CCP-positive cases and healthy controls
wGRS45_G + −− − + 2.41 2.30 2.52 0.6667 >7.79 33 85 6370 15 489
wGRStag_G + + −− + 2.52 2.42 2.62 0.7039 >8.49 37 87 6370 15 489
wGRSfull_G + − + − + 2.42 2.35 2.49 0.7875 >9.51 44 90 6370 15 489
wGRSHLA_G − + − + 2.40 2.33 2.48 0.7563 >1.54 40 88 6370 15 489
wGRSfull_SG + − + + + 2.64 2.45 2.85 0.8013 >10.81 28 95 1978 (1269 smoke) 1224 (851 smoke)
Anti-CCP-negative cases and healthy controls
wGRSfull_G + − + − + 1.43 1.38 1.48 0.6205 >9.27 32 82 2868 15 489
Validation
All cases and controls
wGRS_full_G + − + − + 1.98 1.87 2.11 0.7175 >8.70 30 92 2200 1856
Anti-CCP-positive cases and healthy controls
wGRStag_G + + −− + 2.50 2.26 2.76 0.6937 >7.39 32 89 1406 1856
wGRSfull_G + − + − + 2.50 2.31 2.69 0.7774 >8.73 36 92 1406 1856
wGRSHLA_G −− + − + 2.61 2.41 2.83 0.7632 >3.53 36 92 1406 1856
The OR shown are from the logistic regression testing the association of each weighted genetic risk score (wGRS) with rheumatoid arthritis (RA). Sensitivity and specificity values were based on the high-risk threshold being set at the 5th quintile and are
shown in the threshold column.
AUC, area under ROC curve; CCP, cyclic citrullinated peptide; ROC, receiver operator characteristic; SNP, single-nucleotide polymorphism; wGRSfull_G, wGRS including all 45 susceptibility SNPs, five HLA amino acids and gender; wGRStag_G, wGRS
including all 45 susceptibility SNPs, HLA tag SNP and gender; wGRSHLA_G, wGRS containing five HLA amino acids and gender; wGRSfull_SG, wGRS containing 45 susceptibility SNPs, five HLA amino acids, smoking and gender.
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3cost without compromising the predictive accuracy. Comparison
of our full wGRS to a more practical wGRS containing only
imputed HLA amino acids at HLA-DRB1, HLA-DPB1, HLA-B
and gender showed that removing the 45 SNPs from the model
decreased sensitivity from 44% to 40% and speciﬁcity from
90% to 88% (AUC 0.79, 0.76, respectively, table 2). This trans-
lates to 269 fewer patients being classed as high risk in the
reduced model. Although a signiﬁcant increase in information
was gained by including the additional susceptibility markers
(LR χ
2 1130.72, using 45° of freedom, p=1.91×10
−207), this
statistically signiﬁcant improvement in the model translates to a
minimal clinical improvement, showing that each new suscepti-
bility variant identiﬁed for RA is likely to improve the model;
however, this improvement will be small. This is shown by the
SNP-only model, incorporating 45 SNPs (wGRS45_G), which
shows poor discriminatory ability (AUC 0.66) (ﬁgure 1).
It should also be noted that determining the sensitivity and
speciﬁcity of each model is threshold dependent. The choice of
threshold by which individuals can be classed as high risk is
arbitrary and can be altered to the requirements of the test.
Although ROC curves are useful to estimate the sensitivity and
speciﬁcity of a model they do not take into account the prevalence
of the disease in the population; therefore, even a high AUC may
be of little use when the disease in question is rare in the general
population. RA has a prevalence of only 1%, therefore general
population screening with an AUC of approximately 80% is
unlikely to prove informative.
12 Screening could be more inform-
ative in identifying individuals at risk of developing disease in
groups already deemed to be at high risk due to environmental
factors, such as family history and smoking. The selection of indi-
viduals for primary prevention trials is currently of great interest in
RA research. Identifying individuals with a family history of RA
who can then be stratiﬁed by other environmental and genetic risk
factors for long-term follow-up may help identify pre-disease risk
factors (serological or immunological), which will help to reﬁne
risk prediction models.
Our wGRS including all known RA susceptibility markers to
date shows an improvement over previously published studies
including fewer genetic susceptibility variants (Karlson et al
3 AUC
0.66 in an NHS cohort, 0.75 in a Swedish Epidemiological
Investigation of Rheumatoid Arthritis (EIRA) cohort), Kurreeman
et al
5 AUC 0.71 and Chibnik et al
6 AUC 0.66). Although the
improvement of our model is not substantial compared to that
shown by Karlson et al
3 this may be due to the inclusion of clinical
risk factors such as smoking and age in their model. It should also
be noted that European samples used in Kurreeman et al
5 will
have some overlap with those used in the validation stage of our
study. In comparison to these earlier studies we have shown a
greater increased risk of RA when we compare individuals in the
highest risk group to those in the median risk group (OR 6.38,
95% CI 5.81 to 7.01) (Karlson et al
3 NHS cohort, OR 2.85, 95%
CI 1.75 to 4.64; EIRA 3.36, 95% CI 2.27 to 4.97; Chibnik et al
6
OR 3.0, 95% CI 1.7 to 4.7). The results of our study (AUC 0.80)
are comparable to genetic risk score analysis in other autoimmune
diseases, for example coeliac disease (AUC 0.85)
13 and type one
diabetes (AUC ∼0.90).
14 15
A limitation of our study is that several of the RA susceptibil-
ity SNPs were originally identiﬁed in our large discovery dataset
of 11 366 cases and 15 489 controls. Therefore, the results of
our modelling could be inﬂated due to over-ﬁtting. However,
we addressed this issue by testing our models in an independent
validation dataset of 2200 cases and 1856 controls, which
showed similar results.
Although we were able to include gender in our model, age is
also a risk factor for RA; however, these data were not available
for all subjects in our cohort and therefore were not included. It
is possible that predictive accuracy would have been improved
had age been included. A further limitation in the current study
is that smoking status could only be classiﬁed as ‘ever or never’,
whereas it is likely that pack-years or the smoking habits before
diagnosis may be more important.
It should be noted that the OR reported in genome-wide
association studies may not accurately represent the true relative
risks as many of these studies include RA patients with long-
term established disease and are largely seropositive. Therefore,
care must be taken when evaluating the predictive accuracy of
genetic models as they often perform better in the populations
in which they are developed, and the performance of a model
can be affected by differences in populations, genotype frequen-
cies, phenotypic effect sizes and disease incidence.
Figure 1 GRStag_G: wGRS containing 45 SNPs, a single HLA-DRB1
tag SNP and gender. GRSfull_G: wGRS containing 45 SNPs, all
variation at the HLA region (HLA-DRB1, HLA-DPB1, HLA-B) and gender.
GRSHLA_G: wGRS containing all variation at the HLA (HLA-DRB1,
HLA-DPB1, HLA-B) and gender. GRS45_G: wGRS containing 45
susceptibility SNPs and gender. AUC, area under the curve; CCP, cyclic
citrullinated peptide; ROC, receiver operator characteristic; SNP,
single-nucleotide polymorphism; wGRS, weighted genetic risk score.
Figure 2 Distribution of the wGRS containing 45 SNPs, all variation
at the HLA region (HLA-DRB1, HLA-DPB1, HLA-B) and gender in
anti-CCP-positive cases (blue) and healthy controls (red) from the
discovery dataset. Individuals were classed as high risk if they had a
risk score greater than 9.51, indicated by the solid line. CCP, cyclic
citrullinated peptide; SNP, single-nucleotide polymorphism; wGRS,
weighted genetic risk score.
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heritability of RA,
2 and further genetic studies will account for a
signiﬁcantly larger proportion of heritability, although we have
shown that the addition of susceptibility loci with modest
effects is unlikely to improve classiﬁcation signiﬁcantly.
In summary, we have shown that in RA, even with all known
genetic susceptibility variants (45 loci and amino acids at
HLA-DRB1, HLA-DPB1 and HLA-B), prediction performance
remains modest for the general population but could be used to
identify at-risk individuals in suitably designed targeted screens.
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